Enclomiphene vs TRT: Which Is Right for You?
For a man with secondary hypogonadism — low testosterone driven by inadequate pituitary signalling rather than testicular failure — the choice between enclomiphene and exogenous testosterone is not 'which works better.' Both raise testosterone. They do so via opposite physiologic pathways, with sharply different consequences for fertility, testicular size, and reversibility. The right answer depends almost entirely on whether the patient cares about preserving spermatogenesis. If yes, enclomiphene is the obvious starting point and TRT is the contingency. If no, TRT is more potent, more predictable, and FDA-approved — enclomiphene is none of those things. This comparison breaks down the mechanism, the trade-offs, and the realistic decision tree, then maps it back to the telehealth platforms that prescribe enclomiphene.
How Each Works
| Dimension | TRT (exogenous testosterone) | Enclomiphene |
|---|---|---|
| Mechanism | Directly replaces testosterone from outside the body | Stimulates the HPG axis to produce more testosterone endogenously |
| LH and FSH | Suppressed — the HPG axis shuts down | Elevated — the HPG axis is activated |
| Spermatogenesis | Suppressed — causes azoospermia in most men within months | Maintained or improved |
| Testicular size | Atrophies over time | Maintained or increased |
| Testosterone levels achieved | Higher and more predictable | Moderate — typically 400–700 ng/dL |
| FDA approval | Yes (multiple formulations) | No — off-label, compounded |
| Route | Injection, cream, gel, troche, oral (KYZATREX) | Oral tablet (compounded) |
| Monthly cost | $80–$250/mo depending on formulation | $60–$150/mo via compounding |
Who Should Choose Enclomiphene
- Men who want to preserve fertility or are actively trying to conceive — enclomiphene maintains spermatogenesis; TRT causes azoospermia.
- Men who want to avoid testicular atrophy — a common and often permanent side effect of long-term TRT.
- Men with secondary hypogonadism where the HPG axis is intact but under-signalling — enclomiphene works by fixing the signal, not bypassing it.
- Men who want to avoid the commitment of lifelong TRT — enclomiphene can be cycled or discontinued more cleanly.
- Younger men (20s–30s) for whom fertility and testicular function are long-term priorities.
Who Should Choose TRT
- Men with primary hypogonadism (testicular failure) — enclomiphene can't help if the testes can't respond to LH.
- Men who need reliably high testosterone levels — TRT is more potent and predictable.
- Men who have completed their family and are not concerned about fertility.
- Men who have already tried enclomiphene or clomiphene without adequate response.
- Older men (50+) for whom fertility is not a consideration and symptom relief is the priority.
Enclomiphene vs Clomiphene (Clomid): What's Different?
Clomid (racemic clomiphene) contains both the trans-isomer (enclomiphene) and the cis-isomer (zuclomiphene) in roughly equal proportions. Zuclomiphene has a long half-life and accumulates in tissue, which is associated with mood changes, fatigue, and visual disturbances in some men. Enclomiphene alone avoids the zuclomiphene burden, making it better tolerated for long-term use. Both raise LH, FSH, and testosterone; enclomiphene does so with a cleaner side-effect profile.
Telehealth Platforms That Prescribe Enclomiphene
Because enclomiphene is not FDA-approved as a finished drug, it is dispensed through compounding pharmacies. Several telehealth platforms in our network include it in their TRT or men's health formulary.
Bottom Line
Enclomiphene is the right starting point for men with secondary hypogonadism who care about fertility, testicular volume, or reversibility. It is also a credible bridge therapy for men who want to test whether endogenous production can be revived before committing to lifelong TRT. Where enclomiphene fails — primary hypogonadism, inadequate response after 8–12 weeks at 25 mg/day, or symptom burden severe enough to need testosterone in the upper-normal range — TRT remains the more reliable option. The decision is rarely permanent: men can move from enclomiphene to TRT if response is inadequate, and a subset of men successfully come off TRT through restart protocols that lean on enclomiphene or hCG. Pick the lever that matches the priority, and revisit at the 12-week lab draw.